CureVac N.V.
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in…
Biotechnology
DE, Tübingen [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared CureVac N.V. (CVAC) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 36,972.82 | 12,670.30 | 584.01 | 282.25 | -1,045.34 | 0.00 | 21.8412 | 41.32 | -0.7623 | -19.2547 | -0.07 | -0.07 | 6.8104 | - - | ||
| Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| Moderna, Inc. MRNA | 41.11 | 2.86 7.48% | 13,325 vs. 6,548 | 15,819.00 | 167.00 | -1,175.00 | -1,185.00 | 12,431.00 | -3.0800 | -8.5828 | 0.0000 | 0.2096 | -7.0359 | -0.0917 | -0.0702 | 3.7508 | 384.00 | ||
| CureVac N.V. CVAC | 2.66 | 0.10 3.91% | 473 vs. 471 | 596.00 | 12.00 | -70.00 | -101.00 | -1,636.00 | -0.3100 | -2.2038 | 0.0000 | -2.3694 | -5.7022 | -0.1579 | -0.1022 | 2.0371 | 224.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.